When cells in the body die, they release DNA. This DNA, known as cell-free DNA (cfDNA), makes its way into the bloodstream where it gets chopped up by enzymes, and in minutes to hours, the liver pulls ...
Cell-free DNA (cfDNA) sequence analysis to screen for fetal aneuploidy can incidentally detect maternal cancer. Additional data are needed to identify DNA-sequencing patterns and other biomarkers that ...
Researchers combined protein biomarkers, cfDNA analysis, and machine learning to open opportunities for early-stage ovarian cancer screening and diagnostics. The cfDNA fragmentome is a genome-wide ...
Androgen pathway gene expression and response to hormonal therapy in prostate cancer (SWOG S1216). This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include ...
A novel, blood-based test developed using fragmentomic features of cell-free DNA (cfDNA) detects colorectal cancer (CRC) with a 90.4% sensitivity and shows consistent performance across stages and ...
A new study combines cfDNA fragmentomes and protein biomarkers to vastly improve early detection of ovarian cancer, offering a cost-effective and robust tool for mass screening. Study: Early detection ...
Donor-derived cell-free DNA can aid detection, diagnosis, and monitoring of antibody-mediated rejection after kidney transplantation. Donor-derived cell-free DNA (dd-cfDNA) is a non-invasive biomarker ...
Liver transplant is a lifesaving surgery, but a significant number of patients experience organ rejection or other complications. A study by scientists at Georgetown University and MedStar Health has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results